Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.
It is now difficult to manufacture the first-generation smallpox vaccine, as the process could not comply with current safety and manufacturing regulations. In this study, a candidate non-clonal second-generation smallpox vaccine developed by Sanofi-Pasteur from the Lister strain has been assessed using a cowpox virus challenge in mice. We have observed similar safety, immunogenicity and protection (from disease and death) after a short or long interval following vaccination, as well as similar virus clearance post-challenge, with the second-generation smallpox vaccine candidate as compared to the traditional vaccine used as a benchmark.
Ferrier-Rembert
Audrey
A
Unité de Virologie, Centre de Recherches du Service de Santé des Armées (CRSSA) Emile Pardé, F-38702 Grenoble, France.
Drillien
Robert
R
Meignier
Bernard
B
Garin
Daniel
D
Crance
Jean-Marc
JM
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D023482:Bioterrorism; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002478:Cells, Cultured; D002642:Chick Embryo; D002522:Chlorocebus aethiops; D015605:Cowpox / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D015608:Cowpox virus / Q000472:pathogenicity*; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D012899:Smallpox / Q000276:immunology / Q000401:mortality / Q000517:prevention & control; D012900:Smallpox Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D014616:Vaccinia virus / Q000145:classification / Q000276:immunology*; D014709:Vero Cells
D000914:Antibodies, Viral; D012900:Smallpox Vaccine; D007371:Interferon-gamma